Xospata Reimbursement Marks A First For AML In England
NICE has become the first reimbursement body in Europe to appraise and recommend Astellas Pharma’s drug for relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
You may also be interested in...
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
New medicines under evaluation at the European Medicines Agency.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.